113100-86-0

Basic information

• Product Name: methyl 4-(3-bromopropyl)benzoate
• Synonyms: methyl 4-(3-bromopropyl)benzoate;4-(3-bromopropyl)Benzoic acid methyl ester
• CAS NO: 113100-86-0
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12372
• Mol File: 113100-86-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 310.202°C at 760 mmHg
• Flash Point: 141.405°C
• Appearance: /
• Density: 1.354g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: methyl 4-(3-bromopropyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(3-bromopropyl)benzoate(113100-86-0)
• EPA Substance Registry System: methyl 4-(3-bromopropyl)benzoate(113100-86-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 113100-86-0(Hazardous Substances Data)

Usage

General Description

Methyl 4-(3-bromopropyl)benzoate is an organic compound that belongs to the ester class of chemicals. Its chemical structure consists of a benzene ring with a methyl group and a 3-bromopropyl group attached to it. methyl 4-(3-bromopropyl)benzoate is commonly used in the production of perfumes, flavorings, and pharmaceuticals. It is also known for its use as an intermediate in the synthesis of other organic compounds. Additionally, it can be utilized as a solvent, and it exhibits moderate toxicity and irritation to the skin and eyes if not handled properly.

InChI:InChI=1/C11H13BrO2/c1-14-11(13)10-6-4-9(5-7-10)3-2-8-12/h4-7H,2-3,8H2,1H3

Upstream product

• 67-56-1 methanol 
• 6309-79-1 4-(3-Bromo-propyl)-benzoic acid 
• 73166-52-6 4-((E)-3-oxoprop-1-enyl)-benzoic acid methyl ester 
• 1571-08-0 methyl 4-formylbenzoate 
• 123876-53-9 4-(3-Bromopropyl)-benzoyl chloride 
• 15403-22-2 4-(3-hydroxy-propyl)-benzoic acid methyl ester 
• 106-95-6 allyl bromide 
• 530-62-1 1,1'-carbonyldiimidazole 
• 61266-36-2 methyl 4-(3-hydroxypropynyl)benzoate 
• 637-59-2 1-Bromo-3-phenylpropane 
• 41996-96-7 1-(4-acetylphenyl)-3-bromopropane 
• 619-44-3 methyl 4-iodobenzoate 
• 81631-63-2 p-(methoxycarbonyl)-n-propylbenzene 

Downstream Products

• 431988-82-8 4-(3-{2-[3-(tert-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-5-oxo-pyrrolidin-1-yl}-propyl)-benzoic acid methyl ester 
• 6309-79-1 4-(3-Bromo-propyl)-benzoic acid 
• 123876-53-9 4-(3-Bromopropyl)-benzoyl chloride 
• 401928-16-3 3-[4-(3-(dibutylamino)propyl)benzoyl]-2-butyl-1-benzofuran-5-carboxylic acid 
• 160743-79-3 Diethyl N-[4-(3-[(2,6-diamino-4(3H)-oxopyrimidin-5-yl)thio]propyl)benzoyl]-S-glutamate 
• 160743-77-1 4-{3-[(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)sulfanyl]propyl}benzoic acid methyl ester 
• 160743-78-2 4-(3-[(2,6-diamino-4(3H)-oxopyrimidin-5-yl)thio]propyl) benzoic acid 
• 160743-76-0 methyl 4-(3-thiopropyl)benzoate 
• 223577-17-1 [6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(3-piperidin-1-yl-propyl)-phenyl]-methanone 

Relevant articles and documents

Synthesis method of methyl 4-(3-bromopropyl)benzoate

The invention provides a synthetic method of methyl 4-(3-bromopropyl)benzoate, and relates to the field of medicinal chemistry. The invention provides a new scheme for synthesizing methyl 4-(3-bromopropyl)benzoate from 1-bromo-3-phenylpropane through a two-step one-pot method, and provides a new synthesis route for preparation and synthesis of methyl 4-(3-bromopropyl)benzoate. Moreover, accordingto the synthesis scheme, common raw materials are adopted as reactants, the reaction conditions are proper, the final product is synthesized with the cost remarkably reduced compared with the prior art, the preparation process is simple, the cost is low, large-scale production can be achieved, and a synthesis thought is provided for synthesis of the derivative of the compound.

A nitric oxide donor nature of the benzofuran compounds (by machine translation)

The invention discloses a benzofuran compound with nitrous oxide donor property. The benzofuran compound is a compound shown by a general formula (I) or a pharmaceutically acceptable salt thereof, wherein in the formula, R1 or R2 represents independent hy

EP4 receptor selective agonists in the treatment of osteoporosis

This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.